Interleukin 3 or interleukin 1 abrogates the reconstituting ability of hematopoietic stem cells - PubMed (original) (raw)

Interleukin 3 or interleukin 1 abrogates the reconstituting ability of hematopoietic stem cells

Y Yonemura et al. Proc Natl Acad Sci U S A. 1996.

Abstract

Because of their known myelopoietic activities, both interleukin (IL)-3 and IL-1 are often used in combination with other cytokines for in vitro (ex vivo) expansion of stem cells. We have investigated the effects of IL-3 and IL-1 on in vitro expansion of murine hematopoietic stem cells with long-term engraftment capabilities, using a highly purified progenitor population. Lineage-negative, Ly-6A/E+, c-kit+ bone marrow cells from male mice were cultured in suspension in the presence of stem cell factor, IL-6, IL-11, and erythropoietin with or without IL-3 or IL-1. Kinetic studies revealed an exponential increase in total nucleated cells and about 10-fold enhancement of nucleated cells by IL-3 during the initial 10 days. Addition of IL-3 hastened the development but significantly suppressed the peak production of colony-forming cells. Addition of IL-1 also significantly suppressed the numbers of colony-forming cells. The reconstituting ability of the cultured cells was tested by transplanting the expanded male cells into lethally irradiated female mice. The cells expanded from enriched cells in the absence of IL-3 and IL-1 revealed engraftment at 2, 4, 5, and 6 months, whereas addition of IL-3 or IL-1 to the cultures significantly reduced the reconstituting ability. The results suggest that these cytokines may have a modulatory role on the self-renewal of stem cells and further indicate that the use of IL-3 and IL-1 for in vitro expansion of human stem cells needs to be cautiously evaluated.

PubMed Disclaimer

Cited by

Plerixafor (a CXCR4 antagonist) following myeloablative allogeneic hematopoietic stem cell transplantation enhances hematopoietic recovery.
Green MM, Chao N, Chhabra S, Corbet K, Gasparetto C, Horwitz A, Li Z, Venkata JK, Long G, Mims A, Rizzieri D, Sarantopoulos S, Stuart R, Sung AD, Sullivan KM, Costa L, Horwitz M, Kang Y. Green MM, et al. J Hematol Oncol. 2016 Aug 17;9(1):71. doi: 10.1186/s13045-016-0301-2. J Hematol Oncol. 2016. PMID: 27535663 Free PMC article. Clinical Trial.
Genetic modification of ex-vivo expanded stem cells for clinical application.
Aggarwal R, Pompili VJ, Das H. Aggarwal R, et al. Front Biosci (Landmark Ed). 2010 Jun 1;15(3):854-71. doi: 10.2741/3650. Front Biosci (Landmark Ed). 2010. PMID: 20515730 Free PMC article. Review.
Expansion in vitro of transplantable human cord blood stem cells demonstrated using a quantitative assay of their lympho-myeloid repopulating activity in nonobese diabetic-scid/scid mice.
Conneally E, Cashman J, Petzer A, Eaves C. Conneally E, et al. Proc Natl Acad Sci U S A. 1997 Sep 2;94(18):9836-41. doi: 10.1073/pnas.94.18.9836. Proc Natl Acad Sci U S A. 1997. PMID: 9275212 Free PMC article.
Autocrine production and action of IL-3 and granulocyte colony-stimulating factor in chronic myeloid leukemia.
Jiang X, Lopez A, Holyoake T, Eaves A, Eaves C. Jiang X, et al. Proc Natl Acad Sci U S A. 1999 Oct 26;96(22):12804-9. doi: 10.1073/pnas.96.22.12804. Proc Natl Acad Sci U S A. 1999. PMID: 10536003 Free PMC article.
Hematopoietic stem cell gene therapy:assessing the relevance of preclinical models.
Larochelle A, Dunbar CE. Larochelle A, et al. Semin Hematol. 2013 Apr;50(2):101-30. doi: 10.1053/j.seminhematol.2013.03.025. Semin Hematol. 2013. PMID: 24014892 Free PMC article. Review.

References

1. J Immunol. 1988 May 1;140(9):3040-4 - PubMed
1. Proc Natl Acad Sci U S A. 1964 Jan;51:29-36 - PubMed
1. EMBO J. 1991 Aug;10(8):2111-8 - PubMed
1. J Exp Med. 1978 May 1;147(5):1526-31 - PubMed
1. J Cell Physiol. 1982 Jun;111(3):239-46 - PubMed

Interleukin 3 or interleukin 1 abrogates the reconstituting ability of hematopoietic stem cells - PubMed (original) (raw)